Journal Article

Safety and efficacy of atorvastatin for rebleeding in cerebral cavernous malformations (AT CASH EPOC): a phase 1/2a, randomised placebo-controlled trial

Polster, Sean P, Sorrentino, Matthew, Flemming, Kelly D, Hage, Stephanie, McBee, Nichol, Lee, Cornelia, Lee, Justine, Shenkar, Robert, Ostapkovich, Noeleen, Thompson, Richard E, Jhaveri, Aditya, Kinkade, Serena, Hanley, Daniel F, Awad, Issam A, Iqbal, Javed, Lane, Karen, Girard, Romuald, Alcazar-Felix, Roberto J, Carroll, Timothy J, Treine, Kevin, Stadnik, Agnieszka, Liao, James K

2025

Overview

Cerebral cavernous malformations (CCMs) carry a high risk of rebleeding after symptomatic haemorrhage, with serious clinical sequelae. Atorvastatin was shown to prevent CCM growth and bleeding in animal models. We aimed to assess the safety and efficacy of atorvastatin on rebleeding in patients with CCMs after a symptomatic haemorrhage. We did a phase 1/2a randomised trial at the University of Chicago's CCM Center of Excellence. Patients aged 18–80 years with untreated CCMs who had had symptomatic bleeding from a CCM lesion within the previous year were eligible. Patients were randomly allocated (1:1) to oral atorvastatin (80 mg daily for 2 years) or matching placebo. Investigators, clinical staff, and participants were masked to the assigned treatment. The primary efficacy outcome was the percentage change in mean lesional iron deposition per year, measured by quantitative susceptibility mapping (QSM) on MRI and averaged over 2 years; a decrease would signal potential benefit and an increase a safety concern. The primary efficacy outcome was analysed in the modified intention-to-treat cohort, including patients with at least one annual paired QSM assessment. Safety outcomes included rates of bleeds and serious adverse events necessitating drug discontinuation. This trial is registered at ClinicalTrials.gov (NCT02603328) and is completed. Between July 25, 2018, and July 22, 2022, 326 patients were assessed for eligibility, and 80 patients were allocated either atorvastatin (n=41) or placebo (n=39). 29 (36%) patients were male and 51 (64%) were female. 64 (80%) patients (33 in the atorvastatin group and 31 in the placebo group) had at least one annual paired QSM assessment and were included in the modified intention-to-treat analyses. The mean annual percentage change in lesional QSM was 10·88 (SE 7·29) with atorvastatin versus 12·09 (SE 7·54) with placebo (treatment effect –1·22, 95% CI –22·25 to 19·81; p=0·91). Symptomatic haemorrhage was reported in six patients assigned atorvastatin and seven patients assigned placebo (relative risk 0·81, 95% CI 0·31 to 2·13). No patients had a serious adverse event requiring drug discontinuation and no deaths were recorded. For people with symptomatic haemorrhage caused by CCMs, atorvastatin did not affect the mean change in lesional iron deposition on brain MRI over 2 years when compared with placebo. Atorvastatin was well tolerated and no safety concerns were noted. The study provides a useful framework for biomarker driven drug assessment in a rare disease. US National Institutes of Health.

• Publisher: Elsevier Ltd,Elsevier Limited
• Subject: Adolescent / Adult / Adverse events / Aged / Aged, 80 and over / Animal models / Atorvastatin / Atorvastatin - adverse effects / Atorvastatin - pharmacology / Atorvastatin - therapeutic use / Biomarkers / Bleeding / Cerebral Hemorrhage - drug therapy / Cerebral Hemorrhage - etiology / Clinical trials / Compliance / Complications / Double-Blind Method / Drug dosages / Female / Hemangioma, Cavernous, Central Nervous System - complications / Hemangioma, Cavernous, Central Nervous System - diagnostic imaging / Hemangioma, Cavernous, Central Nervous System - drug therapy / Hemorrhage / Humans / Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects / Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use / Kinases / Magnetic Resonance Imaging / Male / Middle Aged / Patients / Permeability / Placebos / Quality of life / Review boards / Safety / Treatment Outcome / Young Adult